JAZZ

JAZZ

USD

Jazz Pharmaceuticals plc Common Stock (Ireland)

$110.800+2.280 (2.101%)

Prix en Temps Réel

Healthcare
Biotechnologie
Irlande

Graphique des Prix

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$108.520

Haut

$111.170

Bas

$107.660

Volume

0.22M

Fondamentaux de l'Entreprise

Capitalisation Boursière

6.7B

Industrie

Biotechnologie

Pays

Ireland

Statistiques de Trading

Volume Moyen

1.16M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $95.49Actuel $110.800Haut $148.06

Actualités Connexes

PR Newswire

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Voir plus
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR Newswire

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present seven abstracts at the American...

Voir plus
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR Newswire

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after...

Voir plus
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR Newswire

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc....

Voir plus
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Analyst Upgrades

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $210 price target.

Voir plus
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.